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1. Introduction 
Breast cancer is a leading cause of morbidity and mortality among women. Much of the 
morbidity and mortality is associated with metastasis or local recurrence. There has been 
significant research on what can cause breast cancer progression and resistance to treatment. 
Carcinomas are made of transformed cells contained within stromal cells, fibroblasts, and 
immune cells. Difficulty in determining definite causal pathways of development of 
resistance and metastases is complicated by the heterogeneity of breast cancers. There are 
many different subtypes of breast cancer, each with certain unique phenotypes and 
genotypes. There has been shown 3 subsets of mammary cells: basal stem/progenitor cells, 
luminal progenitors, and non stem luminal cells. Although there is heterogeneity among the 
cell population of breast cancer tumors, there is generally a dominant cell type that allows 
classification of the tumor. There are at least four different breast cancer phenotypes. The 
first is the normal-like phenotype which resembles non cancerous breast cancer. The second 
is the luminal phenotype, generally ER positive and often divided into luminal A and 
luminal B categories. These breast cancers also express E-cadherein, KRT8, KRT18, and 
KRT19. The third category is HER-2 positive phenotype, which is generally ER negative. The 
fourth phenotype, designated as basal-like, generally overexpresses markers characteristic 
of normal mammary gland myoepithelium including EGF, p63, and basal cytokeratins 
KRT14, KRT17, and KRT5/6.  
However, a poorly differentiated phenotype has been established as a hallmark for 
aggressive breast cancers, which has suggested a role of stem cells in breast cancers. Stem 
cells are defined as cells that have the ability to undergo unlimited cell cycle divisions to 
create new stem cells that retain their undifferentiated state and multipotent differentiating 
potential. There are two broad categories of stem cells, embryonic and adult, or somatic, 
stem cells. Embryonic stem cells are found in the inner cell mass of blastocysts and involved 
in the differentiation of the embryo. Somatic stem cells are found in various tissues after 
embryogenesis with the main function of normal tissue repair and renewal. Examples 
include mammary stem cells found in breast tissue and recently associated with breast 
carcinomas, as well as mesenchymal stem cells, found in various locations throughout the 
body, including the bone marrow, and involved in modulating immune response. Many 
believe that the somatic stem cells are not as pluripotent as embryonic stem cells and should 
therefore be considered more as progenitor cells rather than stem cells. Progenitor cells are 
similar to stem cells in their ability for self-renewal and ability to differentiate into multiple 
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cell lineages but with a finite number of cell cycle division and more drive toward 
differentiation than embryonic stem cells. Somatic stem cells and progenitor cells are often 
used interchangeably, as will be the case in this chapter.  
An increase in interest in stem cells began in 1997 when malignant stem cells were found in 
acute myeloid leukemia. Subsequent research revealed stem cells in various other solid 
tumors such as prostate, breast, lung, colon, and brain. The discovery of stem cells in breast 
cancer along with the heterogeneity of breast cancers and ability to develop resistance to 
treatment and relapse helped change the previous theory of each cell having equal 
tumorigenic potential to a preference for a theory suggesting that only certain cells within 
the tumor population allow progression of the tumor. Where these stem cells came from, 
however, is still up for debate. Breast cancers have a very heterogeneous set of phenotypes 
which leads to problems with generalizations of clonal origins of breast cancer stem cells 
(BCSC). As will be discussed in this chapter, there are several theories about breast cancer 
stem cell origins. Research about BCSC has captured the attention of scientists because of 
the undifferentiated character of aggressive breast cancer and the ability of stem cells for 
self-renewal, which may fuel breast cancer tumor progression and metastases. However, 
there are significant complicating variables that must be taken into consideration in BCSC 
research. BCSC are complicated with unknown origin, various pathways linked with a 
variety of physiologic processes as well as the uncertainty of isolating breast cancer stem 
cells due to lack of definite cell markers and BCSC definition. An additional roadblock in 
furthering research on BCSC is the possible need of these cells for a particular niche in 
which to grow. Not only must research concentrate on the characterization and pathways of 
BCSC but also take into account the normal physiologic processes and environmental 
conditions which influence the behaviors of cells and tissues . Additionally, it remains to be 
determined whether different subtypes of breast cancer harbor different types of BCSC.  
In evaluating breast cancer, factors to be considered include subtype of breast cancer, 
prognosis, what causes relapse and why breast cancer tumors can develop resistance to 
therapy. Although stem cells have been suggested to be the culprit for possible relapse and 
resistance to therapy, which is often linked to a poor prognosis, the presence of stem cells 
alone is not indicative of poor prognosis. Indeed, mammary stem cells are found in normal 
breast tissue, shown by studies to be present in the basal epithelial compartment of 
mammary glands. Therefore, it is paramount to determine why stem cells become malignant 
or from where the malignant stem cells came. Despite that the exact nature and role of BCSC 
still remain elusive to researchers, much has been discovered about them since 1997, with 
every day giving more insight into their role in breast cancer. This chapter will give an 
overview of the major players in BCSC research in characterization, pathways, and 
treatments, all suggesting possible future directions in breast cancer research. 
2. Characterizing breast cancer stem cells 
One of the difficulties in research about BCSC remains the elusive definition of the cells. 
Although there is no concrete definition of cancer stem cells, generally, scientists include the 
following two characteristics in determining BCSC: the ability for self-renewal to generate 
another malignant cell and the ability to show lineage-specific differentiation. Even given 
these criteria, characterization of BCSC is further hindered by phenotypes linked to self-
renewability such as ALDH1. These phenotypes will be further discussed later in the 
chapter. Other universally accepted characteristics of BSCS include undifferentiated 
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phenotype and resistance to various breast cancer therapies. The resilience of these cells to 
less than optimal conditions has potentially been attributed to their low mitotic rates, when 
compared to the mitotic rates of their differentiated counterpart.  
An important characteristic of stem cells is their inherent resistance to multiple drugs. This 
multiple drug resistance (MDR) profile is generally believed to be conferred to these cells 
mainly by ATP-binding cassette transporters. BCSC are thought to be associated with 
overexpression of these transporters and the most likely mechanism for failure of 
chemotherapy in these cells (Figure 1). The ATP-binding cassette transporters are able to 
efflux various, unrelated drugs out of cells on which they are present, thus conferring an 
MDR profile to these cancer cells. Multidrug resistance gene 1(MDR1) also is a major cause 
of breast cancer resistance to chemotherapy. Other multi drug resistance-linked genes 
include ABCB1, CCNE1, and MMP9. Although MDR is a significant obstacle to effective 
chemotherapy, MDR appears to be a normal protective function not only in malignant 
cancer cells, but also in their benign counterparts as studies have identified ATP-binding 
cassette transporters in normal tissue stem cells. Importantly, MDR activity is up regulated 
in response to chemotherapy. Of significant concern, these transporters have also been 
found in tumor cells that have not been exposed to chemotherapy, indicating a built in 
obstacle to antineoplastic treatment. Studies have shown that chemotherapy also  
 
 
Fig. 1. MDR gene in breast cancer. 
MDR is a natural defense mechanism in many, non-carcinogenic cells. However, MDR 
genes can be upregulated when exposed to chemotherapy, which can allow for tumor 
proliferation and an increasing stem cell phenotype. Nonetheless, expression of MDR genes 
is not the only factor in determining cancer progression or induced-stem cell phenotype 
after chemotherapy because sole upregulation of these genes do not result in stem cell 
phenotype, only treatment escape.  
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significantly increases tumor enrichment with stem cells, suggesting the idea that MDR 
genes may be involved in stem cell phenotype. However, singularly over expressing MDR 
genes showed that although MDR genes may allow escape from treatment, overexpression 
alone does not cause an increase in stem cell phenotype.  
To help determine a concrete definition for BCSC, researchers have endeavored to find cells 
markers common, or more helpfully, exclusive, to BCSC. Cell markers that have garnered 
significant interest in research include CD44 and CD 24. CD44 is a transmembrane 
glycoprotein which is involved in cell adhesion and migration and has been shown to be 
upregulated in various cancers as well as their metastastes. Studies in which the blockage of 
CD44 led to inhibition of local growth and metastases suggest that CD44 is potentially a 
protective measure in breast cancer tumors. CD24 is a heavily glycosylated cell marker, 
which has been suggested to play a role in tumor migration due to its ability to bind P-
selectin, a lectin expressed by endothelium and platelets. It has been suggested that the 
dynamic nature of the CD marker expression, however, prevents CD44 and CD24 from 
being definite markers for BCSC. Their expression can be influenced by epigenetic factors, 
genomic instability, and epithelial to mesenchymal transition, discussed later in this chapter. 
In addition, other studies have found that CD24 is not a consistent marker for breast cancer 
even though it has been and still continues to be used as a marker for BCSC. Therefore, the 
tide is potentially turning away from using these as the only markers for BCSC. However, 
they are still currently being used extensively by the scientific community to help identify 
BCSC. The usage is supported by studies which show that although the CD markers were 
not found to be consistently expressed in all breast cancer or with an increased stem cell-like 
phenotype, in mammospheres, the stem cell phenotype was present as was the ability to 
differentiate into luminal and basal phenotypes in human breast cancers.  
Mammospheres are discrete clusters of cells that have the ability to survive and proliferate 
in non adherent, non differentiated culture conditions and are indicative of stem cell-like 
characteristics. Studies have shown that mammospheres may be more accurate in studying 
stem cells as more stem cell markers and characteristics were found in the spheroids rather 
than the adherent cultures. The spheroids were also found to be more malignant with 
greater altered chemo sensitivity than their adherent counterpart. Therefore, mammosphere 
formation may be used as a characteristic to help identify BCSC. These studies additionally 
showed that MAPK, Notch, Wnt genes, and aldehyde dehydrogenase (ALDH) are all over-
expressed in breast cancer mammospheres. These markers and pathways have all been 
linked to BCSC by various studies and are accepted as potential BCSC markers. 
Side populations are being investigated as a potential identification method for BCSC. Side 
populations were originally used to establish a population of hematopoietic cells enriched in 
hematopoietic stem cell. They are defined by their ability to efflux the dye Hoechst 33342 
out of the cell determined to be due to ATP-binding cassette transporters. Importantly, this 
side population was also found in breast cancers and irradiated breast cancer tumors were 
discovered to contain side populations enriched in progenitor cells. However, the usage of 
this potential method of identification is hampered by the toxicity of the dye to non-side 
population cells. 
ALDH1 is becoming more important for isolation of BCSC along with usage for 
identification of side populations of breast cancer cells with MDR proteins. ALDH1 is a 
member of a family of ALDH enzymes involved in the detoxification of a wide array of 
aldehydes. Functional enzymatic assays are utilized to detect the presence of ALDH 
enzymes due to the wide array of enzymes within the family. There are some contradictory 
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studies about the frequency of ALDH+ cells within a tumor with one study suggesting it is 
as low as 25% while another study reported finding ALDH+ cells in 23 out of the 33 breast 
cancer tumors tested. Although these studies may appear contradictory in the prevalence of 
ALDH+ cells in breast cancer tumors, studies have shown that ALDH- cells are far less 
tumorigenic than ALDH+ cells, especially the small subset that also displays stem cell 
markers CD44+/CD24-/low. In addition, the ALDH+ tumor exhibited preference for 
forming high-grade, HER2+, hormone receptor negative tumor, all indicative of poor overall 
prognosis. ALDH1 has also been rumored to be an independent prognostic factor in 
predicting metastases in inflammatory breast cancer with the associated BCSC having the 
ability to reconstruct the heterogeneity of the originating breast cancer at the distant site . 
CD133, also known as Prominin-1, has been suggested to identify a subset of BCSC. A 
transmembrane glycoprotein, CD133 has been used in defining a wide array of somatic stem 
cells as well as being elevated in the peripheral blood of patients with metastatic disease. 
CD133 is considered a very important stem cell marker despite not much being know about 
it because of it greater restriction to cancer stem cells unlike CD44 and ALDH. Additionally, 
downregulation of CD133 has been shown to decrease cell growth, cell motility, ability to 
metastasize, and ability to form spheroids in stem cell-like conditions (Figure 2). CD133 may  
 
 
Fig. 2. Role of CD133 in breast cancer. 
CD133 downregulation results in poor mammosphere formation, less metastasis, and less 
proliferation, suggesting a potential target for breast cancer treatment. Furthermore, CD133 
is more specific to breast cancer stem cells than many other markers such as CD44, showing 
additional importance in the role of cancer progression and characterization.  
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also be a successful anti-neoplastic therapeutic target as shown in hepatocellular and gastric 
cancers in addition having a role as a cancer stem cell marker. CD133 is potentially a very 
important cancer stem cell marker in breast cancer specifically as shown by several labs. 
Cells from basal-like breast cancer and mammospheres from ductal carcinomas express high 
levels of CD133. Isolated CD133-specfic breast cancer cells from BRCA-1 lines have greater 
colony forming efficiency and increased proliferative potential, similar to stem cells. Finally, 
CD133 has been identified in a majority of inflammatory breast cancers, an aggressive form 
characterized by extensive lymphovascular invasion. A specific xenograft model of 
inflammatory breast cancer, MARY-X, has not only been shown to contain BCSC-enriched 
spheroids expressing CD133, but these spheroids have also been shown to contain BCSC 
profile of CD44+/CD24-/low and ALDH+.  
3. Origin of breast cancer stem cells 
The origins of BCSC to date still have not been fully elucidated. Indeed, prior to interest in 
stem cells, the theory of breast cancer progression was different as well. The traditional 
theory of breast cancer progression hypothesized that each breast cancer cell has the same 
tumorigenic potential and phenotypic heterogeneity, according to this stochastic model, was 
due to the accumulation of genetic insults in the progenitor cells. As more light was shed on 
the undifferentiated nature of aggressive breast cancer tumors and development of 
therapeutic resistance, a new hierarchical model was suggested. This newer theory believes 
that the progression of breast cancer is due to a subset of cells within the tumor with stem 
cell-like characteristics of self-renewal and multi-lineage differentiation potential, which also 
accounts for the heterogeneity of breast cancer (Figure 3). Further support of 
the hierarchical model is additionally shown by studies in which only a small portion of 
cells within a tumor is shown to lead to tumorigenesis. Moreover, the majority of breast 
cancer cells are very inefficient at tumorigenesis at a cellular level, therefore, only a subset 
within the tumor must be responsible for metastases by invading blood vessels and 
transversing the basement membrane. Within the hierarchical model, the subset of cells 
within breast cancer tumors leading to tumorigenesis has been suggested to be BCSC. This 
returns to the question about where these cells come from. There are a variety of theories on 
the subject. BCSC have been supposed to come from de-differentiation, progenitor cells or 
acquirement of genetic alterations by normal resident cells. Embryonic stem cells have been 
known to have undifferentiated phenotype and ability for multi lineage differentiation. 
BCSC are not quite the same although they have the same basic characteristics. In fact, the 
molecular mechanisms involved in the genesis of BCSC appear to point to a variety of 
pathways common to both stem cells and cancer biology, which will be discussed later. P53, 
a long known cell cycle regulator, has been identified as a key determinant in stem cell-like 
characteristics in breast cancer tumors. The mechanism by which p53 endows breast cancer 
tumors to develop tumor progression is by allowing reprogramming of tumor cells to 
become induced-pluripotent cells (Figure 4). These p53 mutations arise often late in tumor 
progression. There is a clear association between p53 inactivation and the presence of stem 
cell associated transcription factors in breast cancer. Furthermore, there is an increased 
incidence of decreased p53 function in malignant tumors, which implies that decreased p53 
function leads to phenotypic plasticity and reprogramming of tumor cells. Additional 
support is seen in studies where induced p53 function led to an inhibition of induced-
pluripotent cells from their differentiated counterpart. In addition, the involvement of 
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epithelial to mesenchymal transition (EMT), discussed below, has been purported to be 
involved in the creation of BCSC.  
 
 
Fig. 3. Theories of breast cancer progression.  
The old model of breast cancer progression assumed that all breast cells have equal potential 
to become tumorigenic with repetitive insults. The new model contends that the breast cells 
are heterogenous from the start with differing potentials for tumorigenesis, thus resulting in 
heterogenous breast cancers. 
Epithelial to mesenchymal transition is defined as the loss of epithelial characteristics of a 
cell to adopt a more mesenchymal phenotype. EMT is a function of normal development, for 
example, involved in gastrulation of a chicken embryo. However, the mesenchymal 
phenotype typically allows more cell migration and invasion and is the reason EMT is being 
researched in relation to cancer progression and metastases. Although EMT has been 
researched for the past two decades, evidence showing EMT in vivo has been controversial. 
EMT has been identified in breast carcinomas and associated with poor prognosis at both 
the gene and subtype level. Features characterizing EMT include loss of cell to cell adhesion 
via E-cadherein in adherens junctions, occludins and claudins in tight junctions and 
desmoplakin in desmosomes. Aditionally, there is a down regulation of epithelial 
cytokeratins (KRT8, KRT18, KRT19), upregulation of mesenchymal proteins vimentin and 
ACTA2. Importantly, there is increased potential for migration and resistance due to an  
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Fig. 4. p53 in breast cancer progression. 
P53 is integral in regulating the normal cell cycle. Ordinarily, it eventually induces apoptosis 
and growth arrest through various caspases. With loss or mutation of p53, EMT and 
increased stem cell associated transcription factors result in breast cancer progression. 
adoption of dynamic actin microfilament networks and increased resistance to apoptosis. 
EMT has also been shown to be induced by EGF, IGF-1, IGF-2, and TGFb, as well as though 
transcriptional control of E-cadherin by transcription factors such as SNA1, SNA2, ZEB1, 
ZEB2, TWIST, and GSC. Signal pathways such as Wnt, Hedgehog and Notch have also been 
implicated in EMT.  
Cells that are the result of EMT and BCSC are not necessarily the same thing. EMT is 
considered distinct from BCSC generation but has some overlapping factors such as EMT 
cells demonstrate a CD44+/CD24-/low phenotype similar to BCSC. It has been suggested 
that EMT can help create BCSC as shown in studies where overexpression of Snail or TWIST 
lead to the creation of cells with CD44+/CD24-/low expression. EMT has been investigated 
in breast cancer and BCSC research because these cells have been associated with tumor 
metastases as well as aggressive breast cancer and a poor prognosis. Furthermore, EMT is 
implicated in the de-evolution of normal mammary cells to acquire stem cell-like properties. 
EMT is important in breast cancer research not only as a possible origin for BCSC but also 
for prognosis. EMT that may create BCSC promotes the development of refractory and 
resistant breast cancer because BCSC are often resistant to many cancer tx, which ultimately 
leads to breast cancer relapse. EMT can be induced by CD8+T cells with the resulting 
tumors having CD44+/CD24-/low phenotype, potent tumorigenicity, ability to re-estabilish 
an epithelial tumor and increased resistance to therapy further lending credence to the idea 
that EMT is involved in BCSC generation. 
Not only do BCSC lend breast cancer the ability for tumor progression but breast cancer is 
also potentially affected by mesenchymal stem cells (MSC). MSC may have a role in being 
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protective for BCSC, thus affecting breast cancer progression. These cells have been shown 
to migrate to breast cancer tumor site and allow the breast cancer to become resistant to 
therapy. Importantly, MSC play an important role in helping BC cells evade the immune 
system, thus allowing tumor progression. MSC by itself has the ability to promote tumor 
progression by creating cancer associated fibroblasts (CAFs). These CAFs, characterized by 
SDF-1 are established in tumor stroma and leads to the creation of metastases, angiogenesis 
and other pro-tumorigenic factors; however, further details are beyond the scope of this 
chapter. 
4. Pathways 
Important pathways that have been implicated in BCSC include Hedgehog, Notch, Wnt, 
p53, and TGFB. TGFB, an immunosuppressive cytokine that is involved in wound healing, 
fibrosis, and cell cycle regulation has been shown to be critical in BCSC behavior. 
Importantly, loss of TGFB may enhance breast cancer motility (thus leading to metastases) 
via EMT, as discussed earlier. This increased motility may be due to the fact that TGFB is 
responsible for cell cycle inhibition and blocking de novo cancer formation. Loss of TGFB is 
associated with an increase the Sca1 marker, showing an increase in the luminal progenitor 
cells within the tumor. Additionally, TGFB results in a decrease in side population cells, 
characterized by the ability to efflux Horest dye, which is thought to be enriched with 
progenitor cells. Furthermore, TGFb was silenced in a cell population with the 
CD44+/CD24-/low phenotype, thus further supporting the fact that TGFb is a tumor 
suppressor. 
Wnt pathway involves secreted growth factors involved in a wide range of cell processes 
and has been shown to be regulatory in nature of stem cell maintenance and carcinogenesis. 
There are two broad categories in this pathway: canonical and non-canonical pathways. The 
canonical pathway, including Wnt1, is b-catenin-dependent while the non-canonical 
pathway, including Wnt5a, is b-catenin-independent. The canonical pathway is associated 
with stem cell maintenance or expansion by suppressing differentiation and promoting self-
renewal. Exogenous administration of Wnt to normal mammary stem cells results in an 
expansion of stem cells with an increase in self-renewal ability. Furthermore, Lp5, a receptor 
for Wnt signaling, is present in the same location as mammary stem cells in the basal-
epithelial compartment of the mammary gland, as previously mentioned. A decreased in 
Lp5 results in the loss of stem cell activity in the mammary gland. The canonical pathway is 
b-catenin dependent, as previously mentioned, therefore, it follows that a gain of function 
mutation resulting in increased b-catenin activity results in increased mammary stem cell 
self renewal. Although the canonical Wnt pathway is involved in stem cell maintenance, it 
has also been implicated in tumorigenesis from stem cells and luminal progenitor cells as 
shown in studies where there is an increase in stem cells and Sca1, a marker for luminal 
progenitor cells, in tumors with overexpressed Wnt1. On the other hand, decreased Wnt5a 
in breast cancer tumors have been implicated in early relapse and poor prognosis. Wnt 1 of 
the canonical Wnt pathway is unregulated and Wnt5a is downregulated in breast cancer 
cells when compared to normal mammilary cells, indicating that the Wnt5a has tumor 
suppressive ability similar to TGFb (discussed above). The two opposing Wnt pathways 
appear to exert effects on each other to maintain normal cellular function. When the 
canonical pathway is suppressed by the non-canonical pathway, there is a decrease in stem 
cell phenotype.  
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Importantly, the Wnt pathway and TGFb are connected since TGFb tumor suppressive 
function appears to involve antagonism of the canonical Wnt pathway by Wnt5a. The two 
are interconnected further because TGFb regulates Wnt5a expression in mammary gland 
while Wnt1 of the canonical pathway mediates TGFb effects on branching during breast 
development. The data suggests that TGFb and Wnt5a can inhibit the canonical Wnt 
pathway, redirecting the mammilary tumor cells to adopt a more basal-like characteristic. 
The mechanism for this tumor suppression by TGFb has been reported to be due to the fact 
that TGFb acting through Wnt5a inhibits b-catenin, thus initiating tumor suppression by 
limiting stem/progenitor cell populations (Figure 5). 
 
 
Fig. 5. TGFb and Wnt pathways interplay in breast cancer. 
TGFb and Wnt5a both act as tumor suppressors. TGFb, when inhibited, induces epithelial-
to-mesenchymal transition, leading to breast cancer progression. Wnt1 is normally inhibited 
by Wnt5a, leading to suppressed ability for self-reneal and de-differentiation. When b-
catenin is not inhibited by Wnt5a, Wnt1 leads to increased self renewal and decreased 
differentiation, both of which lead to breast cancer progression. Therefore, Wnt1 and Wnt5a, 
along with TGFb, work against each other to help maintain normal cell physiology.  
The hedgehog pathway has been implicated in sustaining cancer stem cells through self-
renewal. The pathway was first discovered in Drosophila melanagaster and is a major 
regulator of cell proliferation, differentiation, and stem cell maintenance. The link to cancer 
was established while studying a rare familial disease, Gorlin syndrome, in 1996. Secreted 
Hedgehog ligands bind their transmembrane receptor Patch, which causes Smo release and 
dissociation of transcription factors Gil1, Gil2, and Gil 3 from Fu and SuFu. These 
transcription factors lead to transcription of cyclin D, cyclin E, Myc and EGF factors, 
enhancing carcinogenesis. In the absence of the Hedgehog ligands, the transmembrane 
receptor Patch associates with Smo, effectively blocking Smo function. Thus, Hedgehog 
inhibitors, such as cyclopamine, are being looked at as potential anti-neoplastic agents 
(Figure 6). Additionally, TFGb has been demonstrated to upregulate factors in the 
Hedgehog pathway. Further support of a role in cancer is shown by studies in which the 
hedgehog pathway has been implicated in progression from non-invasive phenotype to 
invasive phenotype in ductal carcinoma. An important fact of which to take note, however, 
is the fact that Hedgehog is also intimately involved in normal developmental processes as 
well, causing potential difficulties implementing Hedgehog inhibitors as anti-tumorigenic 
agents. 
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Fig. 6. Promotion of carcinogenesis through Hedgehog. 
With Hedgehog ligand association with PATCH, smo is released, allowing smo to function 
causing dissociation of transcription factors. This causes an increase in transcriptional 
activity producing Cyclin D, Cyclin E, Myc and EFG factors, all of which lead to 
carcinongenesis. In the absence of Hedgehog ligand, PATCH associates with smo, 
effectively blocking smo function and ultimately inhibiting carcinogenesis, thus suggesting 
the utility of Hedgehog inhibitors such as cyclopamine in breast cancer treatment.  
The Notch pathway has been implicated in normal cell proliferation control and apoptosis 
as well as the development of a variety of organs. This pathway has been demonstrated to 
be abnormally regulated in cancer stem cells, including BCSC, leading to uncontrolled BCSC 
self-renewal. The Notch receptors are bound by ligands called Delta-like and Jagged. The 
bound receptors are proteolytically cleaved by ADAM protease family and y-sectretase, 
allowing sequestration into the nucleus. Once in the nucleus, the transcription of genes 
inhibiting cell differentiation and increasing cell proliferation ensues. The released 
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intracellular domain of Notch acts as a transcriptional co-activator to promote transcription 
of downstream targets of the recombination signal sequence binding protein Jk such as Myc 
and Cyclin D1 (Figure 7). Additionally, Notch transmembrane receptors for Notch proteins 
Notch 1-4 have been found in many stem cells. Studies have shown that treatment of ductal 
carcinomas with Notch inhibitors have led to the formation of fewer mammospheres, 
further supporting evidence of Notch playing a key role in mammary epithelial cell 
proliferation and differentiation. In fact, studies nearly a decade ago provided evidence for a 
role of Notch in breast cancer. These studies showed hyperproliferation of normally 
mammary cells in a dose-dependent manner by Notch pathway activation of constitutively 
active Notch receptors. Notch inhibitors are being considered in clinical trials also because 
Notch signaling has been implicated in breast cancer to resistance to radiation therapy.  
 
 
Fig. 7. Role of Notch in breast cancer. 
The intracellular domain of Notch is cleaved by ADAMS and y –secretase after being bound 
by Delta-like and Jagged ligands. The cleaved portions are then sequestered in the nucleus 
where they act as transcription cofactors resulting in increased Myc and Cyclin D, 
promoting carcinogenesis. Also, Notch inhibitors have been demonstrated to decrease 
mammosphere formation, further suggesting the importance of Notch in breast cancer 
therapy. 
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5. Treatments 
Since the discovery of stem cells in breast cancer, these cells have also been the focus of 
research as potential targets for anti-neoplastic treatment. If these cells allow cancer 
progression, resistance, and recurrence, it is logical that treatments concentrated on stem cell 
suppression would lead to more efficacious breast cancer treatment. Importantly, long-term 
efficacy is doubtful since renewal of stem cells is always a possibility. Nonetheless, there are 
have many proposed therapies targeted at BCSC and their pathways. To date, several 
potential treatments have been suggested against the MDR profile of BCSC including 
UHRF1, dofequidor fumarate, isotetrandrine. UHRF1 plays a role in treating breast cancer by 
inhibiting MDR1 promoter activity and expression. Studies have shown that overexpression 
of UHRF1 can induce deacetylation of histonesH3 and H4 on the MDR1 promoter. This 
deacetylation leads to a loss of binding to transcription factors MyoD, CBP, and p300, 
ultimately suppression MDR1. These cells have been shown to have increased sensitivity to 
chemotherapy agents that are transported by p-glycoprotein. Dofequidor fumarate, an orally 
active quinilone compound, has been shown to decrease MDR profile by inhibiting p-
glygoprotein, MDR1 or both. Indeed, phase III clinical trials have shown a decrease in chemo-
resistance in patients who have not previously received treatment. The compound is thought 
to work by inhibiting ABCG2/BCRP, which is higher in side populations than non side 
population cells, which results in an increased sensitivity to anti-neoplastic treatment. 
Another agent found to be efficacious against the MDR profile associated with BCSC is 
isotetrandrine, an isoquinoline alkaloid extracted from Caulis manhoniae. This agent has 
been discovered to result in MDR reversal through inhibition of p-glycoprotein-mediated 
MDR as has phenybutenoids derived from the rhizomes of Zingiber cassumunar, both acting 
as a potent chemo-sensitizing agent in the treatment against breast cancer. Additionally, IL-24 
has recently gained attention as a potential anti-neoplastic treatment based on its anti-tumor 
effects via induction of apoptosis. Other anti-BCSC agents include salinomycin, an agent that 
targets cancer stem cells of epithelial origin. This agent has been shown to decrease the 
population of CD44+/CD24-/low within breast cancer. Although not specifically shown to 
inhibit breast cancer progression, cyclopamine has been demonstrated to inhibit progression 
of other cancers through the Hedgehog pathway, which is responsible for maintenance of 
CD44+/CD24-/low population in breast cancer.  
Since de-differentiation is a major focus as a potential origin of BCSC and the de-
differentiated phenotype is associated with aggressive breast cancers, it follows that agents 
that can induce differentiation could serve as possible agents antagonistic to stem cell 
creation and survival, leading to improved prognosis and treatment efficacy. Retinoids are 
the forerunners for differentiation therapy and has been shown to be successful as seen in 
acute myeloid leukemia M3 therapy where all-trans retinoic acid is currently being used. Of 
note, BRCA1 has been shown to be integral in differentiation in breast cancer. BRCA1 
knockdown is present in breast cancers with increased mammosphere formation, increased 
ALDH1 cells and increased BCSC.  
It is imperative also to consider the interaction of the immune system with breast cancer 
cells prior to initiating targeted treatment against BCSC. The helper T cell phenotype (Th1 
phenotype), has been found to be more anti-neoplastic than the counterbalancing Th2 
phenotype. Th1 phenotype have effects that may be bimodal, however, since the 
inflammatory nature of the Th1 response can cause DNA damage leading to malignant cell 
transformation, while also allowing anti-tumorigenic actions, perhaps to eliminate these  
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malignant cells, as seen by micrometastases to sentinel lymph nodes creating an increased 
Th1 phenotype. The Th2 phenotype, which studies show to be more clearly linked to pro-
tumorigenic processes, demonstrates a facilitative effect on cancer via release of Il-4, which 
prevents chemo-sensitivity and escape from immune detection.  
Pathways associated with BCSC have also been targeted in breast cancer research. There is 
significant evidence of a role for Hedgehog and Wnt, on stem cells in breast cancer, 
however, there is difficulties associated with inhibiting these pathways because they are also 
involved in normal somatic stem cells required in development. Additionally, since Numb, 
an inhibitor of the Notch pathway, has been shown to have decreased activity in BCSC, 
targeted therapies against Notch have made it to clinical trials unfortunately however, with 
limited success. Much of the ineffectuality of the treatments has been attributed to potential 
cross talk with other pathways.  
6. Conclusion 
Breast cancer research has come a long way in uncovering the unique characteristics of stem 
cells found within breast cancers that make them an important aspect in breast cancers as both 
a reason for resistance and progression as well as a potential target for anti-neoplastic 
treatment. Although much has been discovered about BCSC since their introduction into 
breast cancer research back in 1997, there is still a lot to be figured out. There have been a lot of 
characteristic that have been found helping identify BCSC, however, there is still a lack of a 
concrete definition. Indeed, it may be not only unrealistic to determine a single definition of 
BCSC, but also counterproductive. Since there are such a variety of breast cancers and 
treatments vary accordingly, maybe it is only natural that the definition of these BCSC would 
also vary. Even after stem cells have been identified, it is difficult to specifically target these 
cells. Given that BCSC, whether or not they result directly from normal stem cells, have a lot of 
pathways common to both the abnormal and normal stem cells. This makes it difficult to 
inhibit these pathways without altering normal cellular processes necessary for normal cell 
survival as well. Determination of the development and origin of BCSC would be greatly 
helpful in establishing specific treatments focused on these malignant cells. Given the plethora 
of information already discovered about BCSC and the vast areas still being investigated, 
research has shown how critical BCSC are in the fight against breast cancer.  
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